YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
the inspection conducted from January 27 to January 31, 2025
Observations are largely around improvement of procedures and practices
Subscribe To Our Newsletter & Stay Updated